The results of the recent Canakinumab Antiinflammatory Thrombosis Outcome Study (CANTOS) trial, Cardiovascular Inflammation Reduction Trial (CIRT), and Colchicine Cardiovascular Outcomes Trial (COLCOT)
1-3 emphasize the promise of targeting specific inflammatory pathways for lowering cardiovascular risk. While recent studies have focused on the interleukin-1β (IL-1β)–interleukin-6 (IL-6)–C-reactive protein (CRP) axis,
4 a range of proinflammatory cytokines have been implicated in atherosclerosis.
5 In a recent mendelian randomization study examining multiple cytokines, we found genetically predicted levels of monocyte-chemoattractant-protein–1 (MCP-1) to be associated with higher risk of coronary heart disease (CHD) and ischemic stroke.
6 The presence of MCP-1 recruits monocytes to the arterial wall, and experimental studies of atherosclerosis suggest that targeting MCP-1 signaling attenuates atherosclerosis progression and plaque destabilization.
7,8 Circulating MCP-1 levels have been associated with increased long-term risk of incident stroke,
9 but associations with other cardiovascular end points in the general population remain largely unexplored. We leveraged data from 7 population-based cohorts encompassing 21 401 individuals without overt cardiovascular disease and investigated associations of baseline circulating MCP-1 with incident CHD, nonfatal myocardial infarction, and cardiovascular death over a follow-up period extending beyond 20 years.